Fig. 5

PTPRM reduced expression via epigenetic silencing is associated with poor survival and reduced sensitivity to JAK/STAT targeted anti-cancer therapy in pancreatic cancer patients. (A) Kaplan–Meier curve showing reduced expression of PTPRM in patients with pancreatic cancer was significantly associated with shorter overall survival, Log Rank P = < 0.05 (HR = 2; 95% CI = 0.757–4.336; P = < 0.05). Green line represents patients in the top 25-percentile of PTPRM expression and the red line, bottom 25-percentile PTPRM expression in the pancreatic primary tumour cohort. (B) Horizontal bar graph demonstrates the cellular pathways targeted by anti-cancer drugs from GDSC2 (Genomics of Drug Sensitivity in Cancer) project. Drugs targeting “other” category were excluded. (C) Scatter plot illustrating IC₅₀ concentration of JAK/STAT pathway targeting compounds is significantly proportional to DNA methylation of the PTPRM gene promoter in pancreatic cancer cell lines (rho = 0.3, P = < 0.005)